Literature DB >> 22773267

Prediction of the outcome of antenatal hydronephrosis: significance of urinary EGF.

Zhenzhen Li1, Zhanzheng Zhao, Xianghua Liu, Zhiqiang Su, Xiaoping Shang, Jianguo Wen.   

Abstract

BACKGROUND: Down-regulation of epidermal growth factor (EGF) in the renal parenchyma has been demonstrated in children who underwent pyeloplasty due to ureteropelvic junction obstruction (UPJO). Urine levels of EGF were confirmed to parallel this finding before and after surgery. The aim of our study was to evaluate the relationship between urinary EGF (uEGF) concentrations and Society of Fetal Urology (SFU) high-grade hydronephrosis in infants presenting unilateral antenatal hydronephrosis (ANH).
METHODS: This was a prospective study involving 45 infants (33 in the observational group, 12 in the surgical group) who presented with unilateral ANH. Postnatal evaluation included a clinical examination, renal ultrasonography, and voiding cystourethrography. Diuretic renal scans were performed in infants with an initial SFU grade 3 or 4 hydronephrosis or increasing hydronephrosis during follow-up. Pyeloplasty was performed when a well-tempered renogram showed an obstructive drainage curve with a half-life of >20 min and/or an obstructive washout curve pattern during the diuretic phase. We studied the longitudinal changes in SFU hydronephrosis grade and uEGF in each group and compared concentration levels at three time points in both groups. The enzyme-linked immunosorbent assay (ELISA) method was used to measure EGF concentrations in the urine. The results were normalized with urinary creatinine (Cr).
RESULTS: During the first 6 months, from 6 to 12 months, and in the second year of life, median SFU hydronephrosis grade and uEGF levels were 2, 2 (p = 0.015), and 1 (p < 0.01), and 50, 59 (p = 0.015), and 69.5 ng/mg Cr (p < 0.01), respectively, in the observational group. In the first 6 months, preoperatively and at 3-12 months postoperatively, the median SFU hydronephrosis grade and uEGF levels were 4, 4, and 3 (p > 0.05), and 38, 46, (p > 0.05), and 55 ng/mg Cr (p < 0.01), respectively, in the surgical group. uEGF levels in the first 6 months of life were significantly lower in the surgical group than in the observational group (p < 0.01). Patients in the observational group with SFU grade 3-4 hydronephrosis showed higher uEGF levels than those in the surgical group with SFU grade 3-4 in (p = 0.048).
CONCLUSIONS: Urinary EGF changes over time are associated with inverse changes in SFU hydronephrosis grade, which suggests a role for uEGF as a predictive marker of worsening hydronephrosis grades in infants with ANH. uEGF in the first 6 months of life may predict the need for surgery in infants with ANH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22773267     DOI: 10.1007/s00467-012-2243-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  25 in total

1.  Postnatal management of antenatal hydronephrosis using an observational approach.

Authors:  S A Koff
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

2.  Nonoperative management of unilateral neonatal hydronephrosis.

Authors:  S A Koff; K Campbell
Journal:  J Urol       Date:  1992-08       Impact factor: 7.450

3.  Epidermal growth factor suppresses renal tubular apoptosis following ureteral obstruction.

Authors:  W A Kennedy; R Buttyan; E Garcia-Montes; V D'Agati; C A Olsson; I S Sawczuk
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

4.  Natural history of fetal hydronephrosis diagnosed on mid-trimester ultrasound.

Authors:  S Sairam; A Al-Habib; S Sasson; B Thilaganathan
Journal:  Ultrasound Obstet Gynecol       Date:  2001-03       Impact factor: 7.299

5.  Comparison of the diuretic renogram and the pressure perfusion study in children.

Authors:  E J Kass; M Majd; A B Belman
Journal:  J Urol       Date:  1985-07       Impact factor: 7.450

6.  Ureteral obstruction decreases renal prepro-epidermal growth factor and Tamm-Horsfall expression.

Authors:  S Storch; S Saggi; J Megyesi; P M Price; R Safirstein
Journal:  Kidney Int       Date:  1992-07       Impact factor: 10.612

7.  Urinary epidermal growth factor, monocyte chemotactic protein-1, and β2-microglobulin in children with ureteropelvic junction obstruction.

Authors:  Fabio Bartoli; Rosa Penza; Gabriella Aceto; Francesco Niglio; Olinda D'Addato; Valentina Pastore; Vittoria Campanella; Simona Magaldi; Carla Lasalandra; Giovanna Di Bitonto; Loreto Gesualdo
Journal:  J Pediatr Surg       Date:  2011-03       Impact factor: 2.545

8.  MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy.

Authors:  G Grandaliano; L Gesualdo; F Bartoli; E Ranieri; R Monno; A Leggio; G Paradies; E Caldarulo; B Infante; F P Schena
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

9.  Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy.

Authors:  Maria Stangou; Efstathios Alexopoulos; Aikaterini Papagianni; Afroditi Pantzaki; Christos Bantis; Spiros Dovas; Domniki Economidou; Maria Leontsini; Dimitrios Memmos
Journal:  Nephrology (Carlton)       Date:  2009-01-08       Impact factor: 2.506

10.  Outcome analysis of pediatric pyeloplasty as a function of patient age, presentation and differential renal function.

Authors:  Y H Salem; M Majd; H G Rushton; A B Belman
Journal:  J Urol       Date:  1995-11       Impact factor: 7.450

View more
  8 in total

Review 1.  Urinary biomarkers for renal tract malformations.

Authors:  Pedro Magalhães; Joost P Schanstra; Emma Carrick; Harald Mischak; Petra Zürbig
Journal:  Expert Rev Proteomics       Date:  2016-11-15       Impact factor: 3.940

2.  The role of urinary TIMP1 and MMP9 levels in predicting vesicoureteral reflux in neonates with antenatal hydronephrosis.

Authors:  Hamid Mohammadjafari; Alireza Rafiei; Mohammad Abedi; Abdolrasul Aalaee; Ehsan Abedi
Journal:  Pediatr Nephrol       Date:  2014-01-04       Impact factor: 3.714

Review 3.  Comparing accuracy of urinary biomarkers in differentiation of ureteropelvic junction obstruction from nonobstructive dilatation in children.

Authors:  Geminiganesan Sangeetha; Ramesh Babu
Journal:  Pediatr Nephrol       Date:  2022-03-03       Impact factor: 3.651

Review 4.  The use of biomarkers in the diagnosis and treatment of obstruction of the upper urinary tract in children.

Authors:  Zuzana Seifriedova; Hana Flogelova; Jan Sarapatka; Oldrich Smakal; Vladimir Student
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2022-02-03       Impact factor: 1.648

5.  Label-free quantitative urinary proteomics identifies the arginase pathway as a new player in congenital obstructive nephropathy.

Authors:  Chrystelle Lacroix; Cécile Caubet; Anne Gonzalez-de-Peredo; Benjamin Breuil; David Bouyssié; Alexandre Stella; Luc Garrigues; Caroline Le Gall; Anthony Raevel; Angelique Massoubre; Julie Klein; Stéphane Decramer; Frédérique Sabourdy; Flavio Bandin; Odile Burlet-Schiltz; Bernard Monsarrat; Joost-Peter Schanstra; Jean-Loup Bascands
Journal:  Mol Cell Proteomics       Date:  2014-09-09       Impact factor: 5.911

6.  A long-term follow-up in conservative management of unilateral ureteropelvic junction obstruction with poor drainage and good renal function.

Authors:  S Arena; R Chimenz; E Antonelli; F M Peri; P Romeo; P Impellizzeri; C Romeo
Journal:  Eur J Pediatr       Date:  2018-09-12       Impact factor: 3.183

7.  Epidermal growth factor and its influencing variables in healthy children and adults.

Authors:  Sarang Meybosch; Amandine De Monie; Charlotte Anné; Luc Bruyndonckx; Angelika Jürgens; Benedicte Y De Winter; Dominique Trouet; Kristien J Ledeganck
Journal:  PLoS One       Date:  2019-01-24       Impact factor: 3.240

Review 8.  Urinary biomarkers in pelvic-ureteric junction obstruction: a systematic review.

Authors:  Irene Paraboschi; Guglielmo Mantica; Neil R Dalton; Charles Turner; Massimo Garriboli
Journal:  Transl Androl Urol       Date:  2020-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.